Company Analysis Inari Medical, Inc.
1. Summary
Advantages
- The stock's return over the last year (65.23%) is higher than the sector average (-48.03%).
- Current debt level 4.75% is below 100% and has decreased over 5 years from 43.82%.
Disadvantages
- Price (79.97 $) is higher than fair price (69.18 $)
- Dividends (0%) are below the sector average (0.5339%).
- The company's current efficiency (ROE=-0.3519%) is lower than the sector average (ROE=103.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Inari Medical, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | 0% | 0.9% |
| 90 days | 0% | -47.7% | 8% |
| 1 year | 65.2% | -48% | 19.1% |
NARI vs Sector: Inari Medical, Inc. has outperformed the "Healthcare" sector by 113.26% over the past year.
NARI vs Market: Inari Medical, Inc. has outperformed the market by 46.08% over the past year.
Stable price: NARI is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: NARI with weekly volatility of 1.25% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (79.97 $) is higher than the fair price (69.18 $).
Price is higher than fair: The current price (79.97 $) is 13.5% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (464.56) is higher than that of the sector as a whole (-274.25).
P/E vs Market: The company's P/E (464.56) is higher than that of the market as a whole (-80.5).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (7.85) is lower than that of the sector as a whole (256.7).
P/BV vs Market: The company's P/BV (7.85) is lower than that of the market as a whole (51.89).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (7.39) is lower than that of the sector as a whole (56.99).
P/S vs Market: The company's P/S indicator (7.39) is lower than that of the market as a whole (137.42).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (512.11) is higher than that of the sector as a whole (12.51).
EV/Ebitda vs Market: The company's EV/Ebitda (512.11) is higher than that of the market as a whole (-47.95).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -22.37% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-22.37%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-22.73%).
6.4. ROE
ROE vs Sector: The company's ROE (-0.3519%) is lower than that of the sector as a whole (103.63%).
ROE vs Market: The company's ROE (-0.3519%) is higher than that of the market as a whole (-10.25%).
6.6. ROA
ROA vs Sector: The company's ROA (-0.2426%) is higher than that of the sector as a whole (-2.84%).
ROA vs Market: The company's ROA (-0.2426%) is lower than that of the market as a whole (39.65%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-0.2%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (-0.2%) is lower than that of the market as a whole (8.73%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5339%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 06.01.2025 | Hoffman William Director |
Sale | 60.47 | 12 094 000 | 200 000 |
| 16.12.2024 | Hoffman William Director |
Sale | 55.66 | 3 339 600 | 60 000 |
| 16.10.2024 | Hoffman William Director |
Sale | 45.02 | 1 800 800 | 40 000 |
| 28.05.2024 | Hoffman William Director |
Sale | 50.13 | 3 007 800 | 60 000 |
| 28.05.2024 | Hykes Andrew President and CEO |
Sale | 50 | 150 000 | 3 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
